World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
Bandelow B, Allgulander C, Baldwin D, da Conceição Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. The World Journal Of Biological Psychiatry 2022, 24: 118-134. PMID: 35900217, DOI: 10.1080/15622975.2022.2086296.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsRepetitive transcranial magnetic stimulationCognitive behavioral therapyFirst-line treatmentDeep brain stimulationSSRI treatmentBiological Psychiatry (WFSBP) GuidelinesSecond-line medicationsNon-pharmacological treatmentSerotonin reuptake inhibitorsNon-pharmacological interventionsTreatment-resistant casesTranscranial magnetic stimulationWorld FederationTreatment of anxietyPosttraumatic stress disorderTreatment of OCDReuptake inhibitorsMedication treatmentPharmacological treatmentSNRI venlafaxineInternet-CBTConsensus panelMagnetic stimulationBrain stimulationManagement of Patients With Obsessive-Compulsive Disorder: Focus on Pharmacotherapy
Maziero M, Macaya D, Shavitt R, Diniz J, Miguel E, Silva R, Costa D. Management of Patients With Obsessive-Compulsive Disorder: Focus on Pharmacotherapy. Psychiatric Annals 2022, 52: 143-151. DOI: 10.3928/00485713-20220315-01.Peer-Reviewed Original ResearchSelective serotonin reuptake inhibitorsObsessive-compulsive disorderPharmacological treatmentFirst-line pharmacological therapySecond-line pharmacological treatmentPotential clinical situationsHalf of patientsManagement of patientsSerotonin reuptake inhibitorsKnowledge of cliniciansCommon clinical issueTreatment of patientsReports of RCTsTreatment of OCDAdverse eventsSSRI treatmentPharmacological therapyReuptake inhibitorsSignificant morbidityPharmacological strategiesLimited efficacyClinical practiceClinical situationsClinical issuesSocial disability